Variables | Total enrolled patients (n = 41) | UI-EWD monotherapy (n = 23) |
---|---|---|
Age (year)§ | 74 (39–88) | 76 (39–88) |
Gender (Male), n (%) | 31 (75.6) | 32 (74.4) |
The tumor pathology, n (%) | ||
Adenocarcinoma | 33 (80.5) | 17 (73.9) |
Squamous carcinoma | 2 (4.9) | 0 (0.0) |
GIST | 5 (12.2) | 4 (17.4) |
Lymphoma | 1 (2.4) | 2 (8.7) |
Tumor stage, n (%) | ||
1 | 3 (7.3) | 2 (7.0) |
2 | 2 (4.9) | 0 (9.3) |
3 | 6 (14.6) | 3 (16.3) |
4 | 30 (73.2) | 18 (67.4) |
ASA score, (%) | ||
1 | 2 (4.9) | 1 (4.3) |
2 | 7 (17.1) | 4 (17.4) |
3 | 18 (43.9) | 10 (43.5) |
4 | 13 (31.7) | 7 (30.4) |
5 | 1 (2.4) | 1 (4.3) |
Comorbidity, n (%) | ||
HTN | 18 (43.9) | 12 (47.8) |
DM | 12 (29.3) | 5 (21.7) |
Cardiovascular | 13 (31.7) | 7 (30.4) |
CKD | 4 (9.8) | 2 (8.7) |
Systolic blood pressure (mmHg)§ | 108 (74–162) | 108 (74–139) |
Diastolic blood pressure (mmHg)§ | 59 (30–96) | 59 (30–91) |
Heart rate (per min)§ | 92 (51–177) | 84 (51–177) |
Hb (g/dL)§ | 6.7 (3.7–14.0) | 6.7 (3.7–14.0) |
Follow up duration (day) § | 107 (7–956) | 57 (7–607) |